Technical Analysis for KNCQF - Kancera Ab

Grade Last Price % Change Price Change
grade C 0.08 -29.64% -0.0337
KNCQF closed down 29.64 percent on Tuesday, July 30, 2019, on 10 percent of normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A N/A
See historical KNCQF trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Gapped Down Weakness 0.00%

Older signals for KNCQF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company develops drugs for the treatment of leukemia and solid tumors based on blocking survival signals in the cancer cell and on preventing adaptation of the cancer's metabolism. Its drug development projects include ROR inhibitors for the treatment of leukemia and solid tumors; PFKFB inhibitors for reducing cancer's energy supply from glucose to solid tumors; histone deacetylases6 inhibitors that are aimed to neutralize blood cancer by controlling the cancer cell genome; and AZD8797 Fractalkine inhibitors for stopping the tumor growth and relieving severe pain, as well as small molecule inhibitors of epigenetic processes in parasites for the development of various treatments, including malaria and schistosomiasis. Kancera AB (Publ) has a partnership with Recipharm AB to develop and manufacture KAND567, a pharmaceutical candidate that counteracts the onset of autoimmune disorders, as well as neuritis and pain in connection with chemotherapy against cancer. The company was founded in 2010 and is based in Solna, Sweden.
Medicine Biotechnology RTT Cancer Clinical Medicine Pharmaceutical Pain Chemotherapy Solid Tumors Drug Development Oncology Tumor Cancer Treatments Antineoplastic Drugs Energy Supply Leukemia Malaria Autoimmune Disorders
Is KNCQF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 0 bearish and 5 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.123
52 Week Low 0.08
Average Volume 77,000
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 0.0
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0800
Resistance 3 (R3) 0.0800 0.0800 0.0800
Resistance 2 (R2) 0.0800 0.0800 0.0800 0.0800
Resistance 1 (R1) 0.0800 0.0800 0.0800 0.0800 0.0800
Pivot Point 0.0800 0.0800 0.0800 0.0800 0.0800
Support 1 (S1) 0.0800 0.0800 0.0800 0.0800 0.0800
Support 2 (S2) 0.0800 0.0800 0.0800 0.0800
Support 3 (S3) 0.0800 0.0800 0.0800
Support 4 (S4) 0.0800